Antibiotic resistance is usually discussed as one phenomenon. For a discovery team it is more useful as four distinct engineering problems, because a compound series almost always dies to exactly one of them, and the fix is different in each case.
The four mechanism classes
1. Enzymatic inactivation
The organism makes an enzyme that chemically destroys or modifies the compound. The canonical example is the beta-lactamase family, which hydrolyses the beta-lactam ring. Thousands of variants exist, grouped into classes A, B, C and D, and they range from narrow spectrum penicillinases to the carbapenemases described on the carbapenem resistance page. Aminoglycoside modifying enzymes work the same way by acetylating, phosphorylating or adenylylating the drug.
What it means for a series: this is the mechanism most amenable to chemistry. Inhibitor combinations and ring modifications have repeatedly restored activity. It is a solvable problem with a known playbook.
2. Target modification or protection
The binding site changes so the compound no longer fits, or a protein shields it. Examples include gyrA and parC mutations against fluoroquinolones, the mecA gene giving S. aureus a low affinity penicillin binding protein (see MRSA), the vanA operon remodelling the peptidoglycan terminus away from D-Ala-D-Ala, ribosomal methylation against macrolides, and ribosomal protection proteins such as TetM.
What it means for a series: the hardest of the four. If the target has already moved in circulating isolates, medicinal chemistry on the same pharmacophore rarely recovers it. This is the mechanism that justifies killing a scaffold.
3. Efflux
Pumps export the compound before it accumulates. In Gram-negatives the RND family, spanning both membranes, does most of the work: AcrAB-TolC in E. coli, MexAB-OprM in P. aeruginosa, AdeABC in A. baumannii. Many pumps have broad substrate ranges, so one upregulation event raises MICs across several unrelated classes at once.
What it means for a series: often addressable by chemistry. Changes to charge, polarity and shape can reduce recognition by a pump. It is a transport problem, and the Gram-negative bacteria page covers the accumulation rules.
4. Reduced permeability
The compound cannot get in. Porin loss or porin mutation in K. pneumoniae (OmpK35 and OmpK36) is the usual route, frequently combined with a beta-lactamase so that whatever does enter is destroyed. Intrinsic low permeability, as in P. aeruginosa, is the same problem present from the start.
What it means for a series: similar to efflux. It is about the physicochemistry of the molecule rather than the pharmacophore, and it is why so many potent enzyme inhibitors are inactive on whole cells.
How resistance spreads
Two routes. Vertical, through chromosomal mutation under selection, which is slow and stays in the lineage. And horizontal, through plasmids, transposons and integrons, which moves whole cassettes of resistance genes between species and is why a mechanism that appears in one organism turns up shortly afterwards in another. Plasmid carried genes such as qnr, mcr and the carbapenemases are the ones that reshape a whole treatment landscape quickly.
Why a mechanism name changes a program decision
| Mechanism named | Likely fix | Program implication |
|---|---|---|
| Beta-lactamase | Inhibitor combination, ring modification | Keep the scaffold, add a partner |
| Efflux | Reduce pump recognition, change charge and shape | Keep the scaffold, work the periphery |
| Porin loss | Smaller, more polar, self promoted uptake | Physicochemistry programme |
| Target mutation | New binding mode or new target | Usually a reason to stop |
That is the practical value of a read-out that names the mechanism rather than just returning a number. A high MIC tells you the compound failed. The mechanism tells you whether failing was fixable.
The wider picture
Resistance surveillance, priority pathogen lists and the state of the pipeline are covered under antimicrobial resistance, and the organisms that attract the superbugs label are described there. Alternatives to small molecules, including phage therapy and antimicrobial peptides, each have their own resistance story.
Screen a compound below and read which of the four classes the model expects to take it out on each organism.